UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APP	ROVAL
DMB Number:	3235-0287
Estimated averag	ge burden
ours per respon	se 0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																	
1. Name and Address of Reporting Person * CONRAD HERBERT J				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC, 1545 ROUTE 206 SOUTH, SUITE 302					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2018									r (give title belo	 ow)	Other (spec		v)	
(Street) BEDMINSTER, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)		(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		Exec any	Deemed cution Da	ĺ	if Code (Instr. 8)		v	(A) or Dis (D) (Instr. 3, 4		isposed of E		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following	6. Owners Form: Direct (or Indirect) (I) (Instr. 4	hip of Be	Nature Indirect eneficial wnership astr. 4)		
Common	Stock		12/31/2018					A		40,33 (1)	` ′	\$ 0		1,032,90)3		D	,	
indirectly.			Table II -					t uire	onta he fo	ained i orm dis	n this f splays of, or Bo	orm a a cur enefic	are ren	not req	uired to re	nformation espond un ntrol numb	less	SEC	1474 (9-02)
1. Title of	2.	3. Transaction		<i>e.g.</i> , p	uts, calls						tible sec rcisable			le and	8. Price of	9. Number	of 10.		11. Nature
Derivative Conversion			Execution D any		te, if Transaction Code (ear) (Instr. 8)		of		and Expiration Date (Month/Day/Year)		A: U: Se (I:	Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Own Form Deri Secu Dire or In	of vative rity: et (D) direct	p of Indirect Beneficial Ownership (Instr. 4)	
					Code	V	(A)	(D)	Date Exer	cisable	Expirati Date	ion Ti	itle	Amount or Number of Shares					
Repor	ting O	wners																	

Port of the Owner Name (Address	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
CONRAD HERBERT J							
C/O MATINAS BIOPHARMA HOLDINGS, INC	x						
1545 ROUTE 206 SOUTH, SUITE 302	Λ						
BEDMINSTER, NJ 07921							

Signatures

/s/ Jerome D. Jabbour, attorney-in fact for Herbert J. Conrad	01/04/2019
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On December 31, 2018, the Reporting Person was issued 40,337 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB nu	mber.